<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855188</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL027</org_study_id>
    <nct_id>NCT04855188</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of YVOIRE Y-Solution 540</brief_title>
  <official_title>A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Design Investigation to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 540 Versus YVOIRE Volume Plus in Nasolabial Folds Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 540 versus YVOIRE volume plus&#xD;
      in Nasolabial Folds Injection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WSRS responder rate</measure>
    <time_frame>24 weeks after the last injection</time_frame>
    <description>the proportion of subjects with â‰¥ 1 grade improvement on the wrinkle severity rating scale (WSRS) score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Wrinkles in the Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>YVOIRE Y-Solution 540</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YVOIRE volume plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE Y-Solution 540</intervention_name>
    <description>Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.</description>
    <arm_group_label>YVOIRE Y-Solution 540</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE volume plus</intervention_name>
    <description>Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.</description>
    <arm_group_label>YVOIRE volume plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  3 (moderate) or 4 (severe) on the 5-graded WSRS&#xD;
&#xD;
          -  who sign the written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  who have received permanent facial implants&#xD;
&#xD;
          -  who have received semi-permanent fillers&#xD;
&#xD;
          -  who have undergone temporary dermal filler treatment within 12 months&#xD;
&#xD;
          -  who have undergone facial tissue augmentation with fat injections, botulinum toxin&#xD;
             injections, mesotherapy, or cosmetic procedures within 6 months&#xD;
&#xD;
          -  who have a history of anaphylaxis or allergy to lidocaine, hyaluronic acid (HA)&#xD;
             products, or streptococcal protein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong Hee Jin</last_name>
    <phone>82-2-6987-4151</phone>
    <email>jjonghee@lgchem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiyoon Lee</last_name>
    <email>lgclinical@lgchem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

